Schedule 13G ownership disclosure
REIN THERAPEUTICS INC
Common Stock, $0.001 par value · CUSIP: 00887A204
Event date: 2025-09-24
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Voss Value Master Fund, LP
Shares: 699,440.00 · Class: 3.0%
- Voss Value-Oriented Special Situations Fund, LP
Shares: 316,768.00 · Class: 1.3%
- Voss Advisors GP, LLC
Shares: 1,016,208.00 · Class: 4.3%
- Voss Capital, LP
Shares: 2,666,532.00 · Class: 11.3%
- Cocke Travis W.
Shares: 2,666,532.00 · Class: 11.3%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000921895-25-002628
- Form type
- SCHEDULE 13G/A
- Filer
- Rein Therapeutics, Inc.
- CIK
- CIK 1420565
- Filed
- Sep 26, 2025
- Reporting period
- Sep 24, 2025
- Description
- Schedule 13G beneficial ownership